drugset / Trial / NCT05227742

Exploratory Study of Low Dose Psilocybin

NCT05227742

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the present study is to evaluate the feasibility, initial signals of efficacy, and potential mechanisms of action of "microdoses" of psilocybin (i.e., low doses of psilocybin that are not believed to produce mystical-type, transcendent, hallucinogenic, or other overtly salient subjective effects that limit functionality) in the treatment of moderate to severe demoralization (feelings of hopelessness and meaningless that frequently accompany medical illness and other life hardship).

Timeline

Start
2023-08-15
Primary completion
2026-03
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 1 mg Oral
Subject Psilocybin Other / unclassified 2.5 mg Oral
Subject Psilocybin Other / unclassified 5 mg Oral

Indications

No indication recorded.